Company Overview - Origin Materials Inc (NASDAQ:ORGN) focuses on sustainable materials, aiming to replace fossil-based materials with renewable alternatives and is known for its innovative approach to creating carbon-negative materials [1] Stock Split Details - On March 20, 2026, ORGN underwent a reverse stock split at a ratio of 30 for 1, consolidating every 30 shares into one share, approved by shareholders on February 17 and by the board on March 4 [2] - Following the reverse stock split announcement, ORGN's stock price declined during after-hours trading, currently priced at $0.11, reflecting a slight increase of 0.71% with a minimal change of $0.0008 [2] Stock Performance - Over the past year, ORGN's stock has experienced significant fluctuations, with a high of $28.48 and a low of $0.10, and the company's market capitalization is approximately $17.54 million with a trading volume of 4,520,724 shares [3][5] - The reverse stock split aims to increase the stock price and attract more investors [5] Warrant Trading - ORGN's warrants continue to trade on Nasdaq under the ticker symbol "ORGNW," requiring holders to exercise 30 warrants to receive one share of common stock, aligning with the reverse stock split [4]

Core Insights - Nutriband Inc. has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical for $5 million to EarthVision Bio, with the transaction expected to close on December 31, 2025 [2][3] Company Overview - EarthVision Bio is developing sustainable products created by Dr. Gordon Moore, founder of Intel, and Dr. Hans Franke, former chairman of Chevron Europe, focusing on eco-friendly alternatives to plastic, molded fiber, wood, and paper products [3] - Nutriband Inc. will retain 10% of the shareholding in EarthVision Bio following the acquisition [2][3] Financial Implications - Proceeds from the sale of Pocono Pharma will be used by Nutriband Inc. to further develop its AVERSA Fentanyl product, which is projected to achieve annual U.S. sales between $80 million and $200 million [4] Product Development - Nutriband's AVERSA™ technology is designed to prevent the abuse, misuse, and accidental exposure of transdermal drugs, particularly opioids, and is protected by a broad intellectual property portfolio with patents granted in multiple countries [5][6]